NCT05988918
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of Michigan Rogel Cancer CenterInvestigator-initiated
~17 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:ESK981
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression Free Survival
Measured over 4 months after initiating study drug
Conditions
Where it's being run
2 sites across 2 statesMichigan1
Wisconsin1
Study leadership
- Vaibhav Sahai · PRINCIPAL_INVESTIGATOR · University of Michigan
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Progression Free Survival4 months after initiating study drug
Determining efficacy using proportion of patients alive and progression-free at 4 months within each cancer subtype